Prospective, Randomized, Double-Blind, Multicenter phase II trial comparing the efficacy of chemotherapy with cisplatin and gemcitabine plus sorafenib (BAY 43-9006) versus gemcitabine plus cisplatin, and placebo in the treatment of locally advanced Respectively. Metastatic urothelial AB 31/05 - RUTTE 204 - SUSE.

Trial Profile

Prospective, Randomized, Double-Blind, Multicenter phase II trial comparing the efficacy of chemotherapy with cisplatin and gemcitabine plus sorafenib (BAY 43-9006) versus gemcitabine plus cisplatin, and placebo in the treatment of locally advanced Respectively. Metastatic urothelial AB 31/05 - RUTTE 204 - SUSE.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Sorafenib (Primary) ; Cisplatin; Gemcitabine
  • Indications Bladder cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2012 Company (Bayer HealthCare) added as trial sponsor/affiliate as reported by German Clinical Trials Register record.
    • 15 Feb 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003397).
    • 07 Sep 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top